These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 36602598)

  • 21. Lipid lowering therapy in primary and secondary prevention in Austria: are LDL-C goals achieved? : Results from the DA VINCI study.
    Siostrzonek P; Brath H; Zweiker R; Drexel H; Hoelzl R; Hemetsberger M; Ray KK
    Wien Klin Wochenschr; 2022 Apr; 134(7-8):294-301. PubMed ID: 34870742
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [The importance of intensive lipid-lowering therapy after acute coronary syndrome: changing the paradigm to improve the achievement of targets].
    Muccioli S; Giglio C; Annibali G; Cerutti E; Civera S; Casati R; Delnevo F; De Rosa C; Bongioanni S; Colopi M; Gandolfo N; Aranzulla T; Bianchi F; Blandino A; Borrione M; Grossi S; Luceri S; Mabritto B; Carceri C; Meliga E; Parrini I; Pizzuti A; Scrocca I; Sibona Masi A; Tomasello A; Gasco A; Musumeci G
    G Ital Cardiol (Rome); 2022 Jul; 23(7):553-561. PubMed ID: 35771021
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Simulation of Lipid-Lowering Therapy Intensification in a Population With Atherosclerotic Cardiovascular Disease.
    Cannon CP; Khan I; Klimchak AC; Reynolds MR; Sanchez RJ; Sasiela WJ
    JAMA Cardiol; 2017 Sep; 2(9):959-966. PubMed ID: 28768335
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Medium-intensity statin with ezetimibe versus high-intensity statin in acute ischemic cerebrovascular disease (MESIA): A randomized clinical trial.
    Lv X; Liu X; Peng Y; Li W; Wang J; Chen X; Lei J; Tang C; Luo S; Mai W; Cai Y; Fan Q; Liu C; Zhang L
    J Stroke Cerebrovasc Dis; 2024 May; 33(5):107647. PubMed ID: 38431112
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Unmet Need for Further LDL-C Lowering in India despite Statin Therapy: Lipid Association of India Recommendations for the Use of Bempedoic Acid.
    Mehta V; Puri R; Duell PB; Iyengar SS; Wong ND; Yusuf J; Mukhopadhyay S; Pradhan A; Muruganathan A; Wangnoo SK; Kapoor D; Rastogi A; Tiwaskar MH; Mahajan K; Narasingan SN; Agarwala R; Bordoloi N; Soumitra K; Chakraborty R; Shetty S; Saboo B; Khan A; Prabhakar D; Khanna NN; Mehta A; Bansal M; Kasliwal R; Mehrotra R; Chag M; Sheikh A; Sattur GB; Manoria PC; Pareek KK; Pancholia AK; Melinker RP; Nanda R; Kalra D
    J Assoc Physicians India; 2022 Sep; 70(9):11-12. PubMed ID: 36082889
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Effect of PCSK9 Inhibitors on LDL-C Target Achievement in Patients with Homozygous Familial Hypercholesterolemia: A Retrospective Cohort Analysis.
    Alshahrani A; Kholaif N; Al-Khnifsawi M; Zarif H; Mahzari M
    Adv Ther; 2024 Feb; 41(2):837-846. PubMed ID: 38169062
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Benefits and drawbacks of statins and non-statin lipid lowering agents in carotid artery disease.
    Paraskevas KI; Gloviczki P; Antignani PL; Comerota AJ; Dardik A; Davies AH; Eckstein HH; Faggioli G; Fernandes E Fernandes J; Fraedrich G; Geroulakos G; Golledge J; Gupta A; Gurevich VS; Jawien A; Jezovnik MK; Kakkos SK; Knoflach M; Lanza G; Liapis CD; Loftus IM; Mansilha A; Nicolaides AN; Pini R; Poredos P; Proczka RM; Ricco JB; Rundek T; Saba L; Schlachetzki F; Silvestrini M; Spinelli F; Stilo F; Suri JS; Svetlikov AV; Zeebregts CJ; Chaturvedi S; Veith FJ; Mikhailidis DP
    Prog Cardiovasc Dis; 2022; 73():41-47. PubMed ID: 35605696
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Optimizing Post-Acute Coronary Syndrome Dyslipidemia Management: Insights from the North American Acute Coronary Syndrome Reflective III.
    Alanezi M; Yan AT; Tan MK; Bourgeois R; Malek-Marzban P; Beharry R; Alkurtass S; Gyenes GT; Nadeau PL; Nwadiaro N; Jedrzkiewicz S; Gao D; Chandna H; Nelson WB; Goodman SG;
    Cardiology; 2024; 149(3):266-274. PubMed ID: 38290490
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: A randomized, placebo-controlled study.
    Ballantyne CM; Banach M; Mancini GBJ; Lepor NE; Hanselman JC; Zhao X; Leiter LA
    Atherosclerosis; 2018 Oct; 277():195-203. PubMed ID: 29910030
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of the Early Application of Evolocumab on Blood Lipid Profile and Cardiovascular Prognosis in Patients with Extremely High-Risk Acute Coronary Syndrome.
    Hao Y; Yang YL; Wang YC; Li J
    Int Heart J; 2022 Jul; 63(4):669-677. PubMed ID: 35831153
    [TBL] [Abstract][Full Text] [Related]  

  • 31. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes.
    Sahebkar A; Watts GF
    Clin Ther; 2013 Aug; 35(8):1082-98. PubMed ID: 23932550
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bempedoic acid plus ezetimibe fixed-dose combination in patients with hypercholesterolemia and high CVD risk treated with maximally tolerated statin therapy.
    Ballantyne CM; Laufs U; Ray KK; Leiter LA; Bays HE; Goldberg AC; Stroes ES; MacDougall D; Zhao X; Catapano AL
    Eur J Prev Cardiol; 2020 Apr; 27(6):593-603. PubMed ID: 31357887
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Network Meta-Analysis of Randomized Trials Evaluating the Comparative Efficacy of Lipid-Lowering Therapies Added to Maximally Tolerated Statins for the Reduction of Low-Density Lipoprotein Cholesterol.
    Toth PP; Bray S; Villa G; Palagashvili T; Sattar N; Stroes ESG; Worth GM
    J Am Heart Assoc; 2022 Sep; 11(18):e025551. PubMed ID: 36073669
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of routine early treatment with PCSK9 inhibitors in patients undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: a randomised, double-blind, sham-controlled trial.
    Mehta SR; Pare G; Lonn EM; Jolly SS; Natarajan MK; Pinilla-Echeverri N; Schwalm JD; Sheth TN; Sibbald M; Tsang M; Valettas N; Velianou JL; Lee SF; Ferdous T; Nauman S; Nguyen H; McCready T; McQueen MJ
    EuroIntervention; 2022 Dec; 18(11):e888-e896. PubMed ID: 36349701
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Differences in treatment strategies for LDL-cholesterol reduction in a university lipid clinic vs. standard care apart from the use of PCSK9 inhibitors.
    Pinsdorf D; Messiha D; Petrikhovich O; Bahar M; Steinmetz M; Mahabadi AA; Dykun I; Lortz J; Rassaf T; Rammos C
    J Clin Lipidol; 2023; 17(4):504-511. PubMed ID: 37271601
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and safety for the achievement of guideline-recommended lower low-density lipoprotein cholesterol levels: a systematic review and meta-analysis.
    Khan SU; Khan MU; Virani SS; Khan MS; Khan MZ; Rashid M; Kalra A; Alkhouli M; Blaha MJ; Blumenthal RS; Michos ED
    Eur J Prev Cardiol; 2022 Feb; 28(18):2001-2009. PubMed ID: 33624058
    [TBL] [Abstract][Full Text] [Related]  

  • 37. European Physician Survey Characterizing the Clinical Pathway and Treatment Patterns of Patients Post-Myocardial Infarction.
    Qureshi N; Antoniou S; Cornel JH; Schiele F; Perrone-Filardi P; Brachmann J; Sidelnikov E; Villa G; Ferguson S; Rowlands C; González-Juanatey JR
    Adv Ther; 2023 Jan; 40(1):233-251. PubMed ID: 36289145
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Association of Lowering Low-Density Lipoprotein Cholesterol With Contemporary Lipid-Lowering Therapies and Risk of Diabetes Mellitus: A Systematic Review and Meta-Analysis.
    Khan SU; Rahman H; Okunrintemi V; Riaz H; Khan MS; Sattur S; Kaluski E; Lincoff AM; Martin SS; Blaha MJ
    J Am Heart Assoc; 2019 Apr; 8(7):e011581. PubMed ID: 30898075
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term effects of ezetimibe-plus-statin therapy on low-density lipoprotein cholesterol levels as compared with double-dose statin therapy in patients with coronary artery disease.
    Okada K; Iwahashi N; Endo T; Himeno H; Fukui K; Kobayashi S; Shimizu M; Iwasawa Y; Morita Y; Wada A; Shigemasa T; Mochida Y; Shimizu T; Sawada R; Uchino K; Umemura S; Kimura K
    Atherosclerosis; 2012 Oct; 224(2):454-6. PubMed ID: 22892323
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Current lipid lowering treatment and attainment of LDL targets recommended by ESC/EAS guidelines in very high-risk patients with established atherosclerotic cardiovascular disease: Insights from the START registry.
    De Luca L; Arca M; Temporelli PL; Meessen J; Riccio C; Bonomo P; Colavita AR; Gabrielli D; Gulizia MM; Colivicchi F;
    Int J Cardiol; 2020 Oct; 316():229-235. PubMed ID: 32470532
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.